Cetuximab in the first-line therapy of metastatic colorectal carcinoma: Not so CRYSTAL clear

Future Oncology

Volumn 4, Issue 6, 2008, Pages 741-744

  Windsor, Alastair C J ^a   Cohen, Richard G ^a   Jiao, Long R ^b   Stebbing, Justin ^c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL CRAMP; ADJUVANT THERAPY; ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BRAIN INFARCTION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; COLORECTAL SURGERY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FATALITY; EDITORIAL; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; INDIVIDUALIZATION; LIVER METASTASIS; LIVER RESECTION; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; METASTASIS POTENTIAL; METHODOLOGY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; UNITED STATES; VOMITING; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 61449530647     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.6.741     Document Type: Editorial

References (11)

1. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N. Engl. J. Med. 352, 476-487 (2005).
2. Stebbing J: FLEX data, KRAS and ERCC1 testing in oncology. Future Oncol. 4, 471-473 (2008).
3. Jonker DJ, O'Callaghan CJ, Karapetis CS et al.: Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357, 2040-2048 (2007).
4. van der Spek E, Sonke GS: Cetuximab for colorectal cancer. N. Engl. J. Med. 358, 1196; author reply 1196-1197 (2008Y
5. Manek N, Apostolopoulos, C,. Stebbing J: Progression-free versus overall survival and adequate powering in randomised studies. Eur. J. Cancer 44(15), 2092-2094 (2008).
6. van Cutsem E, Nowacki M, Lang I et al.: Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18S) (2007) (Abstract 4000).
7. van Cutsem E, Lang I, D'haens V et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with of without cetuximab: the CRYSTAL experience. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 2).
8. van Cutsern E: KRAS status and efficacy in the CRYSTAL study: 1st line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without cetuximab. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 2).
9. Saltz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
10. Ledermann JA, Leonard P, Seymour M: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med. 345, 145-146 (2001).
11. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19, 3801-3807 (2001).